Orano Med Theranostics, SAS
1 clinical trials · Sponsor
◉ Watch Orano Med Theranostics, SAS
| Record | Firm | Date |
|---|---|---|
| Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors (NCT05283330) | Orano Med Theranostics, SAS | 2022-12-22 |
Track Orano Med Theranostics, SAS automatically
Every clearance here is in the API, with alerts when new ones post.